Clinical Trials
New Trial Tests Cell Therapy for Advanced Parkinson's
A Phase 1/2a clinical trial is evaluating ANPD001 — an experimental cell therapy that involves transplanting dopamine-producing cells into the brains of people with Parkinson's disease. These cells are designed to mature into the same neurons that are lost to Parkinson's, potentially restoring dopamine signaling. The trial is currently enrolling participants with advanced Parkinson's disease to test safety and tolerability.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: The trial is currently enrolling participants with advanced Parkinson's disease to test safety and tolerability.
Limit: An ongoing trial does not prove effectiveness or mean the treatment is available.
First-in-Human Gene Therapy Trial Targets Parkinson's Root Cause
A new first-in-human study is testing ALN-SNCA in adults with early Parkinson's disease. The therapy uses RNA interference to reduce production of alpha-synuclein — the protein that forms the toxic aggregates believed to drive Parkinson's progression. By targeting the root protein of the disease rather than its symptoms, researchers hope to slow or halt neurodegeneration at its source.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: By targeting the root protein of the disease rather than its symptoms, researchers hope to slow or halt neurodegeneration at its source.
Limit: A promising signal is not yet a validated diagnostic test and cannot guide treatment by itself.
Parkinson's Exercise Study Enrolls to Test Movement Interventions
A clinical trial is actively recruiting participants to study the effects of structured exercise programs on Parkinson's disease progression and symptom management. The study aims to quantify how different types, intensities, and durations of physical activity affect motor function, balance, and quality of life in people with Parkinson's — contributing to more evidence-based physical therapy prescriptions.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: The study aims to quantify how different types, intensities, and durations of physical activity affect motor function, balance, and quality of life in people with Parkinson's — contributing to more evidence-based physical therapy prescriptions.
Limit: An ongoing trial does not prove effectiveness or mean the treatment is available.
Breakthrough Treatments
Stem Cell Transplants Show Promise in Two New Trials
Two independent Phase I/II clinical trials — one in Japan using induced pluripotent stem cells (iPS) and one in the US and Canada using human embryonic stem cells (hES) — have reported early results on transplanted dopamine-producing cells in people with Parkinson's. Combined, the trials enrolled 19 participants who received cell transplants into a movement-related brain region called the putamen. Both studies, published in Nature, showed the procedures were generally well-tolerated, with early signs of benefit warranting further study.
Clinical trialLevel: Under evaluationStudy in peopleWhat the study tells us: Both studies, published in Nature, showed the procedures were generally well-tolerated, with early signs of benefit warranting further study.
Limit: An ongoing trial does not prove effectiveness or mean the treatment is available.
ASAP and MJFF Announce $261M for Global Parkinson's Research Network
Aligning Science Across Parkinson's (ASAP), in partnership with the Michael J. Fox Foundation, announced $261 million in new funding for the Collaborative Research Network — supporting 32 international research teams working to map the biological mechanisms of Parkinson's disease. The initiative, which has now invested over $550 million total since its launch, focuses on understanding why Parkinson's varies between individuals and developing better diagnostic tools and targeted treatments.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: The initiative, which has now invested over $550 million total since its launch, focuses on understanding why Parkinson's varies between individuals and developing better diagnostic tools and targeted treatments.
Limit: Results from cells or animals may not reproduce in people.
Lifestyle Interventions
In-Hospital LSVT BIG Training Proves Feasible for Parkinson's Patients
A recent study compared intensive in-hospital LSVT BIG therapy — a specialized physical rehabilitation program using large, exaggerated movements — against a structured progressive rehabilitation program in people with Parkinson's disease. Researchers found LSVT BIG training was both feasible and well-followed by patients during hospitalization, suggesting it can be effectively delivered in acute care settings to improve balance and gait.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: Researchers found LSVT BIG training was both feasible and well-followed by patients during hospitalization, suggesting it can be effectively delivered in acute care settings to improve balance and gait.
Limit: Results from cells or animals may not reproduce in people.
Emerging Research
New Drug Candidate Attacks Two Drivers of Parkinson's at Once
Researchers have developed a novel immunomodulator — 3-Monothiopomalidomide — that simultaneously targets alpha-synuclein aggregation and microglial inflammation in Parkinson's disease models. The drug works by reducing toxic alpha-synuclein clumps while also calming overactive brain immune cells that fuel neurodegeneration. This dual-action approach addresses two key interconnected mechanisms thought to drive Parkinson's progression, offering a potentially more comprehensive treatment strategy than single-target approaches.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: This dual-action approach addresses two key interconnected mechanisms thought to drive Parkinson's progression, offering a potentially more comprehensive treatment strategy than single-target approaches.
Limit: Results from cells or animals may not reproduce in people.
Protein Discovery Reveals How Parkinson's Spreads Between Brain Cells
A new study has identified WDR44 as a protein that drives de novo alpha-synuclein aggregation at the lysosomal membrane — offering new insight into how the toxic protein clumps form and spread between neurons in Parkinson's disease. By understanding this mechanism, researchers may be able to develop therapies that prevent alpha-synuclein aggregation at its earliest stages, potentially stopping the spread of pathology before extensive neuron damage occurs.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: By understanding this mechanism, researchers may be able to develop therapies that prevent alpha-synuclein aggregation at its earliest stages, potentially stopping the spread of pathology before extensive neuron damage occurs.
Limit: Results from cells or animals may not reproduce in people.
Novel Protein Complex Helps Clear Parkinson's-Linked Toxins
Scientists have discovered that the Blm10/PA200 protein complex activates 20S proteasomes to break down alpha-synuclein and can compensate when standard protein disposal pathways are impaired in Parkinson's models. This finding suggests that enhancing this backup clearance mechanism could help remove toxic alpha-synuclein aggregates that accumulate in Parkinson's brains — opening a potential therapeutic route to actively reduce disease-driving protein burden. Generated daily from public research databases. For informational purposes only — not medical advice.
Research studyLevel: Not stated in reportDesign not statedWhat the study tells us: This finding suggests that enhancing this backup clearance mechanism could help remove toxic alpha-synuclein aggregates that accumulate in Parkinson's brains — opening a potential therapeutic route to actively reduce disease-driving protein burden.
Limit: Without randomization, an association may reflect other differences rather than the intervention causing the result.
This report is for informational purposes only. The content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.